Biogen Inc. (NASDAQ:BIIB) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. If you could take a seat? My name is Eric Schmidt, and my pleasure to host this next fireside chat with Biogen. We're delighted to have with us today Chuck Triano, who heads the IR group there at Biogen. Chuck, thank you very much for joining ...

Core Insights - The systemic lupus erythematosus (SLE) treatment landscape is evolving with multiple new therapies in development, including Biogen's litifilimab, AbbVie's Rinvoq, and Bristol Myers Squibb's Sotyktu [1][6] - Rheumatologists view litifilimab as a strong competitor to established biologics, showing a 26% improvement in SRI-4 response over placebo in Phase II trials [2][3] - Rinvoq and Sotyktu have also shown positive Phase II efficacy data, appealing to rheumatologists and patients due to their oral administration [3][4] Emerging Therapies - Rheumatologists are particularly interested in the approval of Rinvoq, Sotyktu, and litifilimab for SLE, especially for skin manifestations [4] - New therapies will need to compete with Benlysta, which remains a preferred choice due to its established safety record and familiarity among rheumatologists [4][5] - AstraZeneca's Saphnelo and Aurinia's Lupkynis have successfully targeted specific patient populations, indicating the importance of niche marketing for new entrants [5] Market Dynamics - As new therapies approach regulatory approval, they are expected to diversify treatment options for SLE patients, but must demonstrate strong efficacy, safety, and ease of administration [6] - The competitive landscape is influenced by the established dominance of Benlysta, which has a strong market presence in both SLE and lupus nephritis [4][6] - Spherix Global Insights provides strategic guidance and market analysis, helping stakeholders navigate the evolving specialty markets [6][7]

CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Bio ...

Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800)Phase 3 clinical data in totality demonstrates biosimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and after switching.1,2GUANGZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen, the publication in the journal Arthritis Research & Therapy of results fr ...

In this articleESALY4523.T-JPBIIBHannah Yoon | The Washington Post | Getty ImagesLeqembi, an Alzheimer's drug from Biogen and Eisai, isn't a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others.Meeks, an English professor based in Ellisville, Mississippi, was diagnosed with an early stage of Alzheimer's last summer ahead of her 50th birthday. That eventually made her a good fit for Leqemb ...

Biogen (BIIB) announced positive initial data from the pivotal cohort (Part B) of its mid to late-stage study evaluating the safety and efficacy of a higher dose regimen of Spinraza (nusinersen) in previously untreated, symptomatic infants with spinal muscular atrophy (SMA).The investigational higher dosing regimen of Spinraza, an antisense oligonucleotide targeting the root cause of SMA, includes two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every four months. Please note that the ...

Biogen Inc. (NASDAQ:BIIB) Morgan Stanley’s 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. We're very pleased to be hosting Biogen today. Fr ...

Biogen Inc. (NASDAQ:BIIB) Morgan Stanley’s 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. We're very pleased to be hosting Biogen today. Fr ...

Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimenHigher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control groupAmong key measures of clinical efficacy, higher dose regimen showed positive trends compared to the approved dosing regimen CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) ...

Biogen (BIIB) stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.BIIB Stock Underperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe company’s stock performance has been below most large drugmakers’ performance. Biogen's revenues declined 3.3% in the first six months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tys ...